GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofil Chemicals & Pharmaceuticals Ltd (BOM:524396) » Definitions » Capex-to-Operating-Income

Biofil Chemicals & Pharmaceuticals (BOM:524396) Capex-to-Operating-Income : 0.00 (As of Dec. 2023)


View and export this data going back to 1994. Start your Free Trial

What is Biofil Chemicals & Pharmaceuticals Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Biofil Chemicals & Pharmaceuticals's Capital Expenditure for the three months ended in Dec. 2023 was ₹0.00 Mil. Its Operating Income for the three months ended in Dec. 2023 was ₹0.86 Mil.

Hence, Biofil Chemicals & Pharmaceuticals's Capex-to-Operating-Income for the three months ended in Dec. 2023 was 0.00.


Biofil Chemicals & Pharmaceuticals Capex-to-Operating-Income Historical Data

The historical data trend for Biofil Chemicals & Pharmaceuticals's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biofil Chemicals & Pharmaceuticals Capex-to-Operating-Income Chart

Biofil Chemicals & Pharmaceuticals Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.15 0.15 0.48 0.08 0.01

Biofil Chemicals & Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Biofil Chemicals & Pharmaceuticals's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Biofil Chemicals & Pharmaceuticals's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biofil Chemicals & Pharmaceuticals's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofil Chemicals & Pharmaceuticals's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Biofil Chemicals & Pharmaceuticals's Capex-to-Operating-Income falls into.



Biofil Chemicals & Pharmaceuticals Capex-to-Operating-Income Calculation

Biofil Chemicals & Pharmaceuticals's Capex-to-Operating-Income for the fiscal year that ended in Mar. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.106) / 7.385
=0.01

Biofil Chemicals & Pharmaceuticals's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / 0.856
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biofil Chemicals & Pharmaceuticals  (BOM:524396) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Biofil Chemicals & Pharmaceuticals Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Biofil Chemicals & Pharmaceuticals's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Biofil Chemicals & Pharmaceuticals (BOM:524396) Business Description

Traded in Other Exchanges
Address
11/12, Sector E, Sanwer Road, Industrial Area, Indore, MP, IND, 452015
Biofil Chemicals & Pharmaceuticals Ltd is an Indian-based pharmaceutical company. The company's operating segment includes Pharma and Chemicals. It generates maximum revenue from the Pharma segment.

Biofil Chemicals & Pharmaceuticals (BOM:524396) Headlines

No Headlines